1-3 of 3
Jessica Lisle
Close
Sort by
Journal Articles

CD33-Deleted Hematopoietic Cells (Trem-Cel) Are Protected from CD33xCD3 Bispecific Antibody Treatment and Produce Significantly Reduced Levels of Inflammatory Cytokines in Preclinical Studies

Jessica Lisle, Sushma Krishnamurthy, Amanda Halfond, Lisa Pechilis, Nate Manalo, Melissa Chng, Brikena Gjeci, Gabriella Angelini, Fulton Norman, Caitlin Lourenco, Hannah Mager, Julia Etchin, Yonina Keschner, Mariana Silva, Bethany Mattson, Laura Barreyro, Christina Guttke, John Lydeard, Julian Scherer, Michelle I Lin, Tirtha Chakraborty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3425.
https://doi.org/10.1182/blood-2023-180216
Published: 2023
Journal Articles

Knock out of CD123 or CLL-1 By CRISPR-Cas9 Editing from Human Hematopoietic Stem Cell Transplants Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment

Chong Luo, Gabriella Angelini, Sushma Krishnamurthy, Jessica Lisle, Meltem Isik, Azita Ghdossi, Christopher Cummins, Michael Pettiglio, Dane Hazelbaker, Gary Ge, Patrick Tavares, Mugdha Nikam, Elizabeth Paik, John Lydeard, Michelle Lin, Tirtha Chakraborty
Journal: Blood
Blood (2021) 138 (Supplement 1): 3818.
https://doi.org/10.1182/blood-2021-146235
Published: 2021
Journal Articles

Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knock-out While Maintaining High Engraftment Potential and Safety

Nipul Patel, Michael Pettiglio, Christopher Cummins, Jeff Pimentel, Anjali Kapuria, Azita Ghodssi, Meltem Isik, Alejandra Falla, Ravindra Amunugama, Jessica Lisle, Shu Wang, Michelle Lin, John Lydeard, Gary Ge, Dane Hazelbaker, Elizabeth Paik, Tirtha Chakraborty
Journal: Blood
Blood (2021) 138 (Supplement 1): 2939.
https://doi.org/10.1182/blood-2021-148007
Published: 2021